Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating oral LP-168 in relapsed or refractory B-cell malignancies is recruiting. Target conditions include CLL/SLL, Waldenström macr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Hairy Cell Leukemia
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• LP-168 (LP-168)

Snippet

Sponsor: Newave Pharmaceutical Inc | Conditions: CLL/SLL, Waldenstrom Macroglobulinemia | Phase 1 | Status: RECRUITING